Regulation of Stem Cell-Based Research in India in Comparison with the US, EU and other Asian Countries: Current Issues and Future Perspectives

Author(s): Jobin Jose*, Teena George, Aaron M. Thomas

Journal Name: Current Stem Cell Research & Therapy

Volume 15 , Issue 6 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Stem cell therapy is applicable for repair and replacement of damaged cells and tissues. Apart from transplanting cells to the body, the stem cell therapy directs them to grow new and healthy tissues. Stem cells in the area of regenerative medicines hold tremendous promise that may help to regenerate the damaged tissues and heal various diseases like multiple sclerosis, heart diseases, Parkinson’s disease, and so on. To prove the safety, efficacy, and for the requirement of a licence for manufacturing and sale, all the stem cell therapies should pass the required criteria and undergo certain examinations of the regulatory agencies. The regulatory authorities review the manufacturing procedures of products to assure its purity and potency. This review summarizes the comparative critical evaluations of existing regulations and developments on the stem cells research in India, USA, EU and Asian regions and also discusses the challenges that have to be overcome and the important points that should be understood to position India as a source of the perspective nation in stem cells around the world.

Keywords: Stem cells, ethical considerations, USA, India, EU, Asia.

[1]
Kalra K, Tomar P. Stem Cell: Basics, Classification and Applications. Am J Phytomed Clin Ther 2014; 2(7): 919-30.
[2]
Wilson JM. Medicine. A history lesson for stem cells. Science 2009; 324(5928): 727-8.
[http://dx.doi.org/10.1126/science.1174935] [PMID: 19423804]
[3]
Abbaspanah B, Momeni M, Ebrahimi M, Mousavi SH. Advances in perinatal stem cells research: a precious cell source for clinical applications. Regen Med 2018; 13(5): 595-610.
[http://dx.doi.org/10.2217/rme-2018-0019] [PMID: 30129876]
[4]
Stewart MC, Stewart AA. Mesenchymal stem cells: characteristics, sources, and mechanisms of action. Vet Clin North Am Equine Pract 2011; 27(2): 243-61.
[http://dx.doi.org/10.1016/j.cveq.2011.06.004] [PMID: 21872757]
[5]
Coli A, Nocchi F, Lamanna R, et al. Isolation and characterization of equine amnion mesenchymal stem cells. Cell Biol Int Rep 2011; 18(1) e00011
[http://dx.doi.org/10.1042/CBR20110004]
[6]
Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004; 36(4): 568-84.
[http://dx.doi.org/10.1016/j.biocel.2003.11.001] [PMID: 15010324]
[7]
Sadan O, Melamed E, Offen D. Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther 2009; 9(12): 1487-97.
[http://dx.doi.org/10.1517/14712590903321439] [PMID: 19821796]
[8]
Krampera M, Pasini A, Pizzolo G, Cosmi L, Romagnani S, Annunziato F. Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 2006; 6(4): 435-41.
[http://dx.doi.org/10.1016/j.coph.2006.02.008] [PMID: 16777484]
[9]
Yamashiro C, Sasaki K, Yabuta Y, et al. Generation of human oogonia from induced pluripotent stem cells in vitro. Science 2018; 362(6412): 356-60.
[http://dx.doi.org/10.1126/science.aat1674] [PMID: 30237246]
[10]
Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: current status and looming challenges. Stem Cell Res Ther 2017; 8(1): 273-9.
[http://dx.doi.org/10.1186/s13287-017-0727-7] [PMID: 29202871]
[11]
Beeravolu N, McKee C, Alamri A, et al. Isolation and characterization of mesenchymal stromal cells from human umbilical cord and fetal placenta. J Vis Exp 2017; 122(122): 55224-9.
[http://dx.doi.org/10.3791/55224] [PMID: 28447991]
[12]
De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World J Stem Cells 2016; 8(3): 73-87.
[http://dx.doi.org/10.4252/wjsc.v8.i3.73] [PMID: 27022438]
[13]
Lennard AL, Jackson GH. Stem cell transplantation. BMJ 2000; 321(7258): 433-7.
[http://dx.doi.org/10.1136/bmj.321.7258.433] [PMID: 10938056]
[14]
Mosna F, Sensebé L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user’s guide. Stem Cells Dev 2010; 19(10): 1449-70.
[http://dx.doi.org/10.1089/scd.2010.0140] [PMID: 20486777]
[15]
Cedar SH. The function of stem cells and their future roles in healthcare. Br J Nurs 2006; 15(2): 104-7.
[http://dx.doi.org/10.12968/bjon.2006.15.2.20372] [PMID: 16493287]
[16]
Mahla RS. Stem Cells Applications in Regenerative Medicine and Disease Therapeutics. Int J Cell Biol 2016; 2016 6940283
[http://dx.doi.org/10.1155/2016/6940283] [PMID: 27516776]
[17]
O’Brien T, Barry FP. Stem cell therapy and regenerative medicine. Mayo Clin Proc 2009; 84(10): 859-61.
[http://dx.doi.org/10.4065/84.10.859] [PMID: 19797773]
[18]
Rink BE, Amilon KR, Esteves CL, et al. Isolation and characterization of equine endometrial mesenchymal stromal cells. Stem Cell Res Ther 2017; 8(1): 166-71.
[http://dx.doi.org/10.1186/s13287-017-0616-0] [PMID: 28701175]
[19]
Jargin SV. Scientific Papers and Patents on Substances with Unproven Effects. Recent Pat Drug Deliv Formul 2019; 13(1): 37-45.
[http://dx.doi.org/10.2174/1872211313666190307162041] [PMID: 30848224]
[20]
Jargin SV. Stem cells and cell therapies in cardiology. Int J Cardiol Res 2019; 2: 10-2.
[21]
Snodin DJ, Ryle PR. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. BioDrugs 2006; 20(1): 25-52.
[http://dx.doi.org/10.2165/00063030-200620010-00003] [PMID: 16573349]
[22]
Kumar S, Singh NP. Stem cells: A new paradigm. ‎. Indian J Hum Genet 2006; 12(1): 1-10.
[http://dx.doi.org/10.4103/0971-6866.25295]
[23]
Ishii T, Pera RA, Greely HT. Ethical and legal issues arising in research on inducing human germ cells from pluripotent stem cells. Cell Stem Cell 2013; 13(2): 145-8.
[http://dx.doi.org/10.1016/j.stem.2013.07.005] [PMID: 23910081]
[25]
Ethical guidelines for biomedical research on human subjects. 2006.https://www.icmr.nic.in/sites/default/files/guidelines/ethical_guidelines_0.pdf
[26]
Tiwari SS, Raman S. Governing stem cell therapy in India: regulatory vacuum or jurisdictional ambiguity? New Genet Soc 2014; 33(4): 413-33.
[http://dx.doi.org/10.1080/14636778.2014.970269] [PMID: 25431534]
[27]
George B. Regulations and guidelines governing stem cell based products: Clinical considerations. Perspect Clin Res 2011; 2(3): 94-9.
[http://dx.doi.org/10.4103/2229-3485.83228] [PMID: 21897884]
[28]
Tiwari SS, Desai PN. Unproven stem cell therapies in India: Regulatory challenges and proposed paths forward. Cell Stem Cell 2018; 23(5): 649-52.
[http://dx.doi.org/10.1016/j.stem.2018.10.007] [PMID: 30344101]
[30]
Viswanathan S, Rao M, Keating A, Srivastava A. Overcoming challenges to initiating cell therapy clinical trials in rapidly developing countries: India as a model. Stem Cells Transl Med 2013; 2(8): 607-13.
[http://dx.doi.org/10.5966/sctm.2013-0019] [PMID: 23836804]
[31]
Heitmeyer C. Biogovernance beyond the state: the shaping of stem cell therapy by patient organizations in India. Med Anthropol 2017; 36(3): 202-16.
[http://dx.doi.org/10.1080/01459740.2016.1264945] [PMID: 28010118]
[32]
Mittal S. Stem cell research: The India perspective. Perspect Clin Res 2013; 4(1): 105-7.
[http://dx.doi.org/10.4103/2229-3485.106408] [PMID: 23533992]
[33]
Bhagavati S. Stem cell therapy: challenges ahead. Indian J Pediatr 2015; 82(3): 286-91.
[http://dx.doi.org/10.1007/s12098-014-1521-5] [PMID: 24992980]
[34]
Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell 2016; 19(2): 154-7.
[http://dx.doi.org/10.1016/j.stem.2016.06.007] [PMID: 27374789]
[35]
Rosemann A. Standardization as situation-specific achievement: regulatory diversity and the production of value in intercontinental collaborations in stem cell medicine. Soc Sci Med 2014; 122: 72-80.
[http://dx.doi.org/10.1016/j.socscimed.2014.10.018] [PMID: 25441319]
[36]
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell 2015; 17(1): 11-22.
[http://dx.doi.org/10.1016/j.stem.2015.06.007] [PMID: 26140604]
[37]
Lo B, Parham L. Ethical issues in stem cell research. Endocr Rev 2009; 30(3): 204-13.
[http://dx.doi.org/10.1210/er.2008-0031] [PMID: 19366754]
[38]
Hayakawa T. Overview: Core technical elements for early product development, evaluation, and control of human cell-based products. Biologicals 2015; 43(5): 410-5.
[http://dx.doi.org/10.1016/j.biologicals.2015.05.010] [PMID: 26272542]
[39]
Burk J, Badylak SF, Kelly J, Brehm W. Equine cellular therapy--from stall to bench to bedside? Cytometry A 2013; 83(1): 103-13.
[http://dx.doi.org/10.1002/cyto.a.22216] [PMID: 23081833]
[40]
Dimmeler S, Ding S, Rando TA, Trounson A. Translational strategies and challenges in regenerative medicine. Nat Med 2014; 20(8): 814-21.
[http://dx.doi.org/10.1038/nm.3627] [PMID: 25100527]
[41]
Stem cell Threapies The Game- Challenging path to FDA Approval. 2018.https://www.lifecyclebio.com/2018/05/15/stem-cell-therapies-game-changing-path-fda-approval
[42]
Martell K, Trounson A, Baum E. Stem cell therapies in clinical trials: workshop on best practices and the need for harmonization. Cell Stem Cell 2010; 7(4): 451-4.
[http://dx.doi.org/10.1016/j.stem.2010.09.004] [PMID: 20887951]
[43]
Dryden VC, Morrison S, Bras R. Using stem cells in clinical cases. J Equine Vet Sci 2013; 33: 872-3.
[http://dx.doi.org/10.1016/j.jevs.2013.08.057]
[44]
Clegg PD, Pinchbeck GL. Evidence-based medicine and stem cell therapy: how do we know such technologies are safe and efficacious? Vet Clin North Am Equine Pract 2011; 27(2): 373-82.
[http://dx.doi.org/10.1016/j.cveq.2011.04.002] [PMID: 21872765]
[47]
Salter B, Zhou Y, Datta S. Making choices: health consumers, regulation and the global stem cell therapy market. BioDrugs 2014; 28(5): 461-4.
[http://dx.doi.org/10.1007/s40259-014-0105-2] [PMID: 24980610]
[48]
FDA ’ s Framework for Regulating Regenerative Medicine Will Improve Oversight . 2019.https://www.pewtrusts.org//media/assets/2019/10/fdasframeworkforregulatingregenerativemedicine_v2.pdf
[49]
Knoepfler P. Stem cells: an insider’s guide. Singapore: World scientific 2013.
[http://dx.doi.org/10.1142/8821]
[50]
Devolder K. The ethics of embryonic stem cell research. Oxford: Oxford University Press 2015.
[http://dx.doi.org/10.1093/acprof:oso/9780199547999.001.0001]
[51]
Blasimme A, Rial-Sebbag E. Regulation of cell-based therapies in Europe: current challenges and emerging issues. Stem Cells Dev 2013; 22(1)(Suppl. 1): 14-9.
[http://dx.doi.org/10.1089/scd.2013.0352] [PMID: 24304069]
[52]
Denoon A, Hitchcock J, Davies JL. The regulation of stem cells in the UK and the EUStem cells in regenerative medicine: Science, regulation and business stratergies First. John Wiley & Sons, Ltd. 2015; pp. 125-46.
[53]
Hoppe N, Morrison M. Governing Stem cells Regenerative medicine in Europe The vision and recommendations from the EUCelLEX project 2018.
[54]
Rosemann A, Sleeboom-Faulkner M. New regulation for clinical stem cell research in China: expected impact and challenges for implementation. Regen Med 2016; 11(1): 5-9.
[http://dx.doi.org/10.2217/rme.15.80] [PMID: 26680327]
[55]
Jiang L, Dong BH. Fraudsters operate and officialdom turns a blind eye: a proposal for controlling stem cell therapy in China. Med Health Care Philos 2016; 19(3): 403-10.
[http://dx.doi.org/10.1007/s11019-016-9692-7] [PMID: 26906907]
[56]
Hara A, Sato D, Sahara Y. New governmental regulatory system for stem cell based therapies in Japan. Ther Innov Regul Sci 2014; 48(6): 681-8.
[http://dx.doi.org/10.1177/2168479014526877] [PMID: 30227468]
[57]
Jung KW. Regulation of human stem cell research in South Korea. Stem Cell Rev Rep 2010; 6(3): 340-4.
[http://dx.doi.org/10.1007/s12015-010-9156-z] [PMID: 20506047]
[58]
Ethics Guidelines for Human Biomedical Research. 2015.http://www.bioethics-singapore.org/images/uploadfile/fullReport.pdf
[59]
Liebert MA. Guidance for human somatic cell therapy and gene therapy. March 1998. Center for Biologics Evaluation and Research, Food and Drug Administration. Hum Gene Ther 1998; 9(10): 1513-24.
[PMID: 9681422]
[60]
Hyun I. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges. J Law Med Ethics 2010; 38(2): 277-85.
[http://dx.doi.org/10.1111/j.1748-720X.2010.00488.x] [PMID: 20579251]
[61]
Bubela T, McCabe C, Archibald P, et al. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. Regen Med 2015; 10(7): 897-911.
[http://dx.doi.org/10.2217/rme.15.51] [PMID: 26565607]
[62]
Gardner J, Faulkner A, Mahalatchimy A, Webster A. Are there specific translational challenges in regenerative medicine? Lessons from other fields. Regen Med 2015; 10(7): 885-95.
[http://dx.doi.org/10.2217/rme.15.50] [PMID: 26541074]
[63]
Sleeboom-Faulkner ME. The large grey area between ‘bona fide’and ’rogue’stem cell interventionsdethical acceptability and the need to in-clude local variability. Technol Forecast Soc Change 2016; 109: 76-86.
[http://dx.doi.org/10.1016/j.techfore.2016.04.023]
[64]
Rosemann A, Bortz G, Vasen F, Sleeboom-Faulkner M. Global regulatory developments for clinical stem cell research: diversification and challenges to collaborations. Regen Med 2016; 11(7): 647-57.
[http://dx.doi.org/10.2217/rme-2016-0072] [PMID: 27622527]
[65]
Schneider CK, Salmikangas P, Jilma B, et al. Committee for Advanced Therapies (CAT); CAT Scientific Secretariat. Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov 2010; 9(3): 195-201.
[http://dx.doi.org/10.1038/nrd3052] [PMID: 20190786]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 6
Year: 2020
Published on: 29 September, 2020
Page: [492 - 508]
Pages: 17
DOI: 10.2174/1574888X15666200402134750
Price: $65

Article Metrics

PDF: 16
HTML: 3